To the Editor: In their meta-analysis, Dr Natanson and colleagues1 described the hurdles they faced in accessing data from HBOC trials conducted by pharmaceutical companies. Although we agree that more transparency is needed to balance corporate and public interests, we consider it unacceptable to draw definite conclusions based on seemingly incomplete data.
Shander A, Javidroozi M, Thompson G. Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death. JAMA. 2008;300(11):1295-1299. doi:10.1001/jama.300.11.1296-b